이식 진단 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of transplant diagnostics Market

The global transplant diagnostics market plays a crucial role in ensuring the success of organ and stem cell transplantation by enabling accurate donor-recipient matching and effective post-transplant monitoring. In 2025, the global transplant diagnostics market was valued at USD 2.69 billion and is projected to grow to USD 2.82 billion in 2026, reaching USD 4.45 billion by 2034, registering a CAGR of 5.89% during the forecast period. North America dominated the market in 2025, accounting for 58.43% of the global share, driven by advanced healthcare infrastructure and a high number of transplant procedures.

Transplant diagnostics include molecular and immunological tests such as HLA typing, crossmatch testing, donor-specific antibody screening, and rejection monitoring. These diagnostics are essential to minimize organ rejection, optimize immunosuppressive therapy, and improve long-term transplant outcomes. Rising investments in precision medicine and molecular diagnostics are further strengthening market growth.

Market Dynamics

Market Drivers

Rising Organ Transplant Procedures and Need for Compatibility Testing

The increasing prevalence of chronic diseases such as end-stage kidney disease, liver failure, and heart disorders has significantly increased the demand for organ transplants worldwide. This rise has directly increased the need for advanced transplant diagnostic tests to ensure donor-recipient compatibility and post-transplant success.

For instance, in 2024, Kidney Care U.K. reported that approximately 6,250 people were on the kidney transplant waiting list in the U.K. The adoption of technologies such as PCR, next-generation sequencing (NGS), and biomarker testing has enabled early detection of rejection and improved clinical decision-making, further driving market growth.

Market Restraints

Limited Availability of Donor Organs

Despite technological advancements, the limited availability of donor organs remains a major restraint. The number of transplant candidates significantly exceeds the number of available donor organs, resulting in fewer transplant procedures and reduced utilization of diagnostic tests.

According to Donate Life America, around 5,600 people in the U.S. die annually while waiting for an organ transplant, highlighting the gap between demand and supply, which indirectly restricts market growth.

Market Opportunities

Rising Investments in Transplant Infrastructure

Growing investments in transplant centers and healthcare infrastructure provide significant growth opportunities. Governments and private institutions are actively promoting organ donation awareness and expanding transplant facilities.

For example, in April 2025, Victoria Hospital announced the launch of a new organ retrieval and transplant center in Bengaluru, India, with an investment of USD 1.1 million, supporting future demand for transplant diagnostics.

Market Challenges

Stringent Regulatory and Reimbursement Policies

Strict regulatory requirements and limited reimbursement coverage pose challenges to market expansion. Transplant diagnostics must meet high safety and accuracy standards, leading to lengthy approval timelines and high development costs. Additionally, partial reimbursement in many regions limits adoption, especially in developing economies.

Market Trends

Shift Toward Non-Invasive Monitoring

A major trend in the transplant diagnostics market is the growing adoption of non-invasive diagnostic technologies. Blood-based biomarker tests and sequencing-based assays reduce the need for invasive biopsies and allow early detection of rejection with minimal patient risk.

In June 2024, Omixon received IVDR approval for its NanoTYPE HLA amplification kit, highlighting the shift toward advanced and less invasive testing solutions.

Segmentation Analysis

By Type

The reagents & consumables segment dominated the market with a 67.33% share in 2026, due to continuous usage of test kits and reagents in transplant diagnostics. The instruments segment is expected to grow steadily with rising transplant infrastructure in emerging economies.

By Testing

Rejection monitoring held the largest market share (46.46% in 2026) as these tests are performed repeatedly after transplantation to ensure long-term graft survival.

By Technology

PCR technology accounted for 26.71% of the market share in 2026, owing to its cost-effectiveness and widespread availability. Meanwhile, NGS is expected to register the highest growth rate due to its superior accuracy and role in personalized medicine.

By Transplant Type

The solid organ transplant segment dominated the market with a 95.21% share in 2026, driven by the high prevalence of chronic diseases requiring organ replacement.

By End-user

Hospitals and transplant centers held the largest market share due to the high concentration of transplant procedures and access to advanced diagnostic infrastructure.

Regional Outlook

In 2025, North America generated USD 1.57 billion in revenue, supported by strong government initiatives, advanced diagnostics adoption, and a large transplant patient base. Europe shows steady growth due to strong research collaborations, while Asia Pacific is projected to record the fastest CAGR, driven by rising chronic disease burden and expanding transplant programs in India, China, and Japan. Latin America and the Middle East & Africa are expected to witness moderate growth with improving healthcare infrastructure.

Competitive Landscape

The market is moderately consolidated, with key players such as Thermo Fisher Scientific, Illumina, Qiagen, and F. Hoffmann-La Roche Ltd. leading through technological innovation, strategic partnerships, and product launches. Other prominent players include Bio-Rad Laboratories, Werfen, BD, and Bruker, contributing to competitive expansion.

Conclusion

The global transplant diagnostics market is expected to witness sustained growth from USD 2.69 billion in 2025 to USD 4.45 billion by 2034, driven by rising organ transplant procedures, advancements in molecular diagnostics, and increasing investments in transplant infrastructure. While challenges such as donor organ shortages and regulatory complexities persist, the growing shift toward non-invasive monitoring and precision diagnostics is strengthening market potential. Overall, transplant diagnostics remain essential for improving transplant success rates and long-term patient outcomes, ensuring steady market expansion over the forecast period.

Segmentation By Type

• Instruments
• Reagents & Consumables
• Software & Service

By Testing

• HLA Typing
• Crossmatch Testing
• Donor-Specific Antibody (DSA) Screening
• Rejection Monitoring
• Infection & Graft Monitoring

By Technology

• PCR
• Next-Generation Sequencing
• Sanger Sequencing
• Flow Cytometry
• Serological Assays
• Others

By Transplant Type

• Solid Organ Transplantation
  • Kidney
  • Liver
  • Lung
  • Others
  • Stem Cell / Bone Marrow Transplantation

By End-user

• Hospitals & Transplant Centers
• Research & Academic Institutions
• Others

By Region

• North America (By Type, Testing, Technology, Transplant Type, End-user, and Country)
  • U.S. (By Transplant Type)
  • Canada (By Transplant Type)
• Europe (By Type, Testing, Technology, Transplant Type, End-user, and Country/Sub-region)
  • Germany (By Transplant Type)
  • U.K. (By Transplant Type)
  • France (By Transplant Type)
  • Spain (By Transplant Type)
  • Italy (By Transplant Type)
  • Rest of Europe (By Transplant Type)
• Asia Pacific (By Type, Testing, Technology, Transplant Type, End-user, and Country/Sub-region)
  • China (By Transplant Type)
  • Japan (By Transplant Type)
  • India (By Transplant Type)
  • Australia (By Transplant Type)
  • South Korea (By Transplant Type)
  • Rest of Asia Pacific (By Transplant Type)
• Latin America (By Type, Testing, Technology, Transplant Type, End-user, and Country/Sub-region)
  • Brazil (By Transplant Type)
  • Mexico (By Transplant Type)
  • Rest of Latin America (By Transplant Type)
• Middle East & Africa (By Type, Testing, Technology, Transplant Type, End-user, and Country/Sub-region)
  • GCC (By Transplant Type)
  • South Africa (By Transplant Type)
• Rest of the Middle East & Africa (By Transplant Type)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disorders, Key Countries/Regions, 2025/2025
• 4.2. Technological Advancements in Transplant Diagnostics
• 4.3. New Product Launches, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Transplant Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Instruments
  • 5.1.2. Reagents & Consumables
  • 5.1.3. Software & Service
• 5.2. Market Analysis, Insights and Forecast - By Testing
  • 5.2.1. HLA Typing
  • 5.2.2. Crossmatch Testing
  • 5.2.3. Donor-Specific Antibody (DSA) Screening
  • 5.2.4. Rejection Monitoring
  • 5.2.5. Infection & Graft Monitoring
• 5.3. Market Analysis, Insights and Forecast - By Technology
  • 5.3.1. PCR
  • 5.3.2. Next-Generation Sequencing
  • 5.3.3. Sanger Sequencing
  • 5.3.4. Flow Cytometry
  • 5.3.5. Serological Assays
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By Transplant Type
  • 5.4.1. Solid Organ Transplantation
    • 5.4.1.1. Kidney
    • 5.4.1.2. Liver
    • 5.4.1.3. Lung
    • 5.4.1.4. Others
  • 5.4.2. Stem Cell / Bone Marrow Transplantation
• 5.5. Market Analysis, Insights and Forecast - By End-User
  • 5.5.1. Hospitals & Transplant Centers
  • 5.5.2. Research & Academic Institutions
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East and Africa

6. North America Transplant Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Instruments
  • 6.1.2. Reagents & Consumables
  • 6.1.3. Software & Service
• 6.2. Market Analysis, Insights and Forecast - By Testing
  • 6.2.1. HLA Typing
  • 6.2.2. Crossmatch Testing
  • 6.2.3. Donor-Specific Antibody (DSA) Screening
  • 6.2.4. Rejection Monitoring
  • 6.2.5. Infection & Graft Monitoring
• 6.3. Market Analysis, Insights and Forecast - By Technology
  • 6.3.1. PCR
  • 6.3.2. Next-Generation Sequencing
  • 6.3.3. Sanger Sequencing
  • 6.3.4. Flow Cytometry
  • 6.3.5. Serological Assays
  • 6.3.6. Others
• 6.4. Market Analysis, Insights and Forecast - By Transplant Type
  • 6.4.1. Solid Organ Transplantation
    • 6.4.1.1. Kidney
    • 6.4.1.2. Liver
    • 6.4.1.3. Lung
    • 6.4.1.4. Others
  • 6.4.2. Stem Cell / Bone Marrow Transplantation
• 6.5. Market Analysis, Insights and Forecast - By End-User
  • 6.5.1. Hospitals & Transplant Centers
  • 6.5.2. Research & Academic Institutions
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
    • 6.6.1.1. By Transplant Type
  • 6.6.2. Canada
    • 6.6.2.1. By Transplant Type

7. Europe Transplant Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Consumables
  • 7.1.3. Software & Service
• 7.2. Market Analysis, Insights and Forecast - By Testing
  • 7.2.1. HLA Typing
  • 7.2.2. Crossmatch Testing
  • 7.2.3. Donor-Specific Antibody (DSA) Screening
  • 7.2.4. Rejection Monitoring
  • 7.2.5. Infection & Graft Monitoring
• 7.3. Market Analysis, Insights and Forecast - By Technology
  • 7.3.1. PCR
  • 7.3.2. Next-Generation Sequencing
  • 7.3.3. Sanger Sequencing
  • 7.3.4. Flow Cytometry
  • 7.3.5. Serological Assays
  • 7.3.6. Others
• 7.4. Market Analysis, Insights and Forecast - By Transplant Type
  • 7.4.1. Solid Organ Transplantation
    • 7.4.1.1. Kidney
    • 7.4.1.2. Liver
    • 7.4.1.3. Lung
    • 7.4.1.4. Others
  • 7.4.2. Stem Cell / Bone Marrow Transplantation
• 7.5. Market Analysis, Insights and Forecast - By End-User
  • 7.5.1. Hospitals & Transplant Centers
  • 7.5.2. Research & Academic Institutions
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
    • 7.6.1.1. By Transplant Type
  • 7.6.2. Germany
    • 7.6.2.1. By Transplant Type
  • 7.6.3. France
    • 7.6.3.1. By Transplant Type
  • 7.6.4. Spain
    • 7.6.4.1. By Transplant Type
  • 7.6.5. Italy
    • 7.6.5.1. By Transplant Type
  • 7.6.6. Rest of Europe
    • 7.6.6.1. By Transplant Type

8. Asia Pacific Transplant Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Instruments
  • 8.1.2. Reagents & Consumables
  • 8.1.3. Software & Service
• 8.2. Market Analysis, Insights and Forecast - By Testing
  • 8.2.1. HLA Typing
  • 8.2.2. Crossmatch Testing
  • 8.2.3. Donor-Specific Antibody (DSA) Screening
  • 8.2.4. Rejection Monitoring
  • 8.2.5. Infection & Graft Monitoring
• 8.3. Market Analysis, Insights and Forecast - By Technology
  • 8.3.1. PCR
  • 8.3.2. Next-Generation Sequencing
  • 8.3.3. Sanger Sequencing
  • 8.3.4. Flow Cytometry
  • 8.3.5. Serological Assays
  • 8.3.6. Others
• 8.4. Market Analysis, Insights and Forecast - By Transplant Type
  • 8.4.1. Solid Organ Transplantation
    • 8.4.1.1. Kidney
    • 8.4.1.2. Liver
    • 8.4.1.3. Lung
    • 8.4.1.4. Others
  • 8.4.2. Stem Cell / Bone Marrow Transplantation
• 8.5. Market Analysis, Insights and Forecast - By End-User
  • 8.5.1. Hospitals & Transplant Centers
  • 8.5.2. Research & Academic Institutions
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
    • 8.6.1.1. By Transplant Type
  • 8.6.2. Australia
    • 8.6.2.1. By Transplant Type
  • 8.6.3. China
    • 8.6.3.1. By Transplant Type
  • 8.6.4. India
    • 8.6.4.1. By Transplant Type
  • 8.6.5. Southeast Asia
    • 8.6.5.1. By Transplant Type
  • 8.6.6. South Korea
    • 8.6.6.1. By Transplant Type
  • 8.6.7. Rest of Asia Pacific
    • 8.6.7.1. By Transplant Type

9. Latin America Transplant Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Instruments
  • 9.1.2. Reagents & Consumables
  • 9.1.3. Software & Service
• 9.2. Market Analysis, Insights and Forecast - By Testing
  • 9.2.1. HLA Typing
  • 9.2.2. Crossmatch Testing
  • 9.2.3. Donor-Specific Antibody (DSA) Screening
  • 9.2.4. Rejection Monitoring
  • 9.2.5. Infection & Graft Monitoring
• 9.3. Market Analysis, Insights and Forecast - By Technology
  • 9.3.1. PCR
  • 9.3.2. Next-Generation Sequencing
  • 9.3.3. Sanger Sequencing
  • 9.3.4. Flow Cytometry
  • 9.3.5. Serological Assays
  • 9.3.6. Others
• 9.4. Market Analysis, Insights and Forecast - By Transplant Type
  • 9.4.1. Solid Organ Transplantation
    • 9.4.1.1. Kidney
    • 9.4.1.2. Liver
    • 9.4.1.3. Lung
    • 9.4.1.4. Others
  • 9.4.2. Stem Cell / Bone Marrow Transplantation
• 9.5. Market Analysis, Insights and Forecast - By End-User
  • 9.5.1. Hospitals & Transplant Centers
  • 9.5.2. Research & Academic Institutions
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
    • 9.6.1.1. By Transplant Type
  • 9.6.2. Mexico
    • 9.6.2.1. By Transplant Type
  • 9.6.3. Rest of Latin America
    • 9.6.3.1. By Transplant Type

10. Middle East and Africa Transplant Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Instruments
  • 10.1.2. Reagents & Consumables
  • 10.1.3. Software & Service
• 10.2. Market Analysis, Insights and Forecast - By Testing
  • 10.2.1. HLA Typing
  • 10.2.2. Crossmatch Testing
  • 10.2.3. Donor-Specific Antibody (DSA) Screening
  • 10.2.4. Rejection Monitoring
  • 10.2.5. Infection & Graft Monitoring
• 10.3. Market Analysis, Insights and Forecast - By Technology
  • 10.3.1. PCR
  • 10.3.2. Next-Generation Sequencing
  • 10.3.3. Sanger Sequencing
  • 10.3.4. Flow Cytometry
  • 10.3.5. Serological Assays
  • 10.3.6. Others
• 10.4. Market Analysis, Insights and Forecast - By Transplant Type
  • 10.4.1. Solid Organ Transplantation
    • 10.4.1.1. Kidney
    • 10.4.1.2. Liver
    • 10.4.1.3. Lung
    • 10.4.1.4. Others
  • 10.4.2. Stem Cell / Bone Marrow Transplantation
• 10.5. Market Analysis, Insights and Forecast - By End-User
  • 10.5.1. Hospitals & Transplant Centers
  • 10.5.2. Research & Academic Institutions
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. South Africa
    • 10.6.1.1. By Transplant Type
  • 10.6.2. GCC
    • 10.6.2.1. By Transplant Type
  • 10.6.3. Rest of Middle East and Africa
    • 10.6.3.1. By Transplant Type

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Hoffmann-La Roche Ltd.
  • 11.2.2. Illumina Inc.
  • 11.2.3. Thermo Fisher Scientific
  • 11.2.4. Qiagen
  • 11.2.5. Admera Health, LLC
  • 11.2.6. Bio-Rad Laboratories Inc.
  • 11.2.7. Bruker
  • 11.2.8. Werfen
  • 11.2.9. BD
  • 11.2.10. Other Prominent Players